The pan-deacetylase inhibitor panobinostat (LBH 589) inhibits DNA methyltransferases in HCC in vitro and in vivo

The novel cinnamic hydroxamic acid pan-deacetylase inhibitor panobinostat (LBH 589) has recently described to posesss cytotoxic effects against HCC by inhibition of protein deacetylases and histone deacetylases. We therefore applied panobinostat to human HCC cell lines (HepG2, Hep3B) in vitro and to a xenograft model in vivo to determine its effect on another epigenetic target, the DNA methyltransferases (DNMT´s).The human hepatoma cell lines HepG2 and Hep3B were treated with panobinostat at 0.1µM and analyzed after 6 to 72h. Furthermore we used a HepG2 xenograft models with NMRI mice. When subcoutaneous tumors…